BioPharma Resources

Investigational drug · Phase 3

Adebrelimab

Also called: SHR-8068, HRS -4642, SHR-4610

Not approved by FDA. In 41 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

41

41 still active

All registered trials

301

Any phase or sponsor naming "Adebrelimab"

First trial start

2024

Mar 2024

Conditions studied

As listed on its trial records.

  • Non-small Cell Lung Cancer
  • Advanced or Metastatic Non-small Cell Lung Cancer
  • Advanced Solid Tumors
  • Carcinoma, Non-Small-Cell Lung
  • Non-squamous Non-small Cell Lung Cancer
  • Advanced Esophageal Squamous Cell Carcinoma
  • Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Malignant Solid Tumors

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Adebrelimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 87 on PubMed

Also in development for Non-small Cell Lung Cancer

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.